Apr 06, 2020
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
Apr 02, 2020
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Apr 02, 2020
Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality
Apr 01, 2020
GenScript Launches Neoantigen Specific Peptide Synthesis Service for Precision Immuno-oncology Therapeutic Development
Apr 01, 2020
Global Immune Checkpoint Inhibitors Market Outlook 2022
Mar 31, 2020
Phio Announces Positive New Data Validating the INTASYL(TM) Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth
Mar 30, 2020
ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology
Mar 30, 2020
Mount Sinai Researchers Discover Potential Boost to Cancer Immunotherapy
Mar 26, 2020
Apexigen To Present At The Upcoming 2020 Solebury Trout Virtual Investor Conference
Mar 26, 2020
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
Mar 25, 2020
TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
Mar 25, 2020
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
Mar 25, 2020
Society for Immunotherapy of Cancer Advocates for Expanded Access to Anti-IL-6 Therapies for Critically Ill Patients
Mar 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer
Mar 24, 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Mar 24, 2020
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
Mar 24, 2020
Aethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer
Mar 23, 2020
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
Mar 17, 2020
4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate
Mar 16, 2020
Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis